ProCE Banner Activity

Anti-BCMA CAR T-Cell Therapy bb2121 in R/R Multiple Myeloma: Updated Phase I Dose-Escalation and Dose-Expansion Results

Slideset Download
Conference Coverage
At active doses, bb2121 induced deep responses independent of BCMA expression and was associated with predominantly low-grade and manageable toxicities.

Released: June 04, 2018

Expiration: June 03, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen